The abstract is read at the publisher; the summary is JClub's.
In the AZTEC randomized trial of 693 preterm infants (<30 weeks gestation), 10 days of prophylactic intravenous azithromycin reduced gut microbial diversity and increased macrolide-resistant genes, including erm (C), persisting through follow-up.
- Why it matters: Early antibiotic exposure in preterm infants can disrupt the developing gut microbiome and resistome, but the specific effects of prophylactic azithromycin—and whether probiotics offset them—were unclear.
- What they did: The double-blind, placebo-controlled study (n = 28 centers) used 16S rRNA gene sequencing, antibiotic susceptibility testing, and quantitative PCR on longitudinal stool samples for 21 days or until discharge.
- The result: Azithromycin lowered alpha diversity and Bifidobacterium while increasing Staphylococcus and Enterobacter/Klebsiella, and it increased macrolide-resistant ARGs with erm (C) present throughout the study; probiotics increased diversity and Bifidobacterium but did not fully reverse azithromycin effects, and combined treatment further increased Enterobacter/Klebsiella and total ARGs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.